ARTICLE | Company News
Kinex Pharmaceuticals, Xiangxue deal
May 28, 2012 7:00 AM UTC
Kinex granted Xiangxue exclusive rights in China, Taiwan and Singapore to develop and commercialize KX02 for cancer. KX02 is a lipophilic dual inhibitor of Src and pretubulin. In the U.S., Kinex sai...